跳至主要内容
临床试验/NCT02079233
NCT02079233已完成1 期

Phase 1 Multiple Dose Trial to Assess the Safety, Tolerability and Efficacy of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers

Sorbent Therapeutics0 个研究点目标入组 25 人开始时间: 2010年5月最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
25
主要终点
Change in fecal sodium content

研究概览

简要总结

This is a study to determine the effect of four different dosing regimens of CLP in normal healthy volunteers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy volunteer is ≥ 18 years of age with BMI of 18-32
  • Females could not be pregnant or breast feeding and had to be using birth control
  • Must have regular bowel habits, typically producing at least 1 daily bowel movement

排除标准

  • Screening 12-lead ECG demonstrating QTc interval >430 msec for males and >450 msec for females, or any cardiac rhythm disorder considered by the Investigator to be clinically relevant
  • History or presence of gastrointestinal conditions
  • Positive drug screen for substances of abuse
  • Positive results for HIV, hepatitis B, or hepatitis C

研究组 & 干预措施

CLP 3.75 g QID

Experimental

Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d on hour before breakfast, lunch, dinner and immediately before bedtime

干预措施: Cross-Linked Polyelectrolyte (CLP) (Drug)

CLP 15 g QD

Experimental

Cross-Linked Polyelectrolyte (CLP) study medication delivered immediately before bedtime

干预措施: Cross-Linked Polyelectrolyte (CLP) (Drug)

CLP 7.5 g BID

Experimental

Cross-Linked Polyelectrolyte (CLP) Study medication delivered b.i.d. one hour before breakfast and dinner

干预措施: Cross-Linked Polyelectrolyte (CLP) (Drug)

CLP 5 g TID

Experimental

Cross-Linked Polyelectrolyte (CLP) Study medication delivered t.i.d. one hour before breakfast, lunch and dinner

干预措施: Cross-Linked Polyelectrolyte (CLP) (Drug)

结局指标

主要结局

Change in fecal sodium content

时间窗: Baseline (Days 3-6) vs. Treatment (Days 10-13)

The primary endpoint was sodium removal from the stool compared between the Baseline period and the Treatment Period.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验